Tecentriq (atezolizumab)

P2, N=88, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Mar 2026 --> Jun 2026 | Trial primary completion date: Mar 2026 --> Jun 2026

P1, N=43, Suspended, University Hospital, Grenoble | Recruiting --> Suspended

P2, N=206, Active, not recruiting, Fondazione Ricerca Traslazionale | Not yet recruiting --> Active, not recruiting | Trial completion date: Apr 2023 --> May 2027 | Trial primary completion date: May 2022 --> May 2027

From 2,239 titles, four relevant trials (N=1,364) were included: two randomized controlled trials of atezolizumab, and two retrospective studies of nivolumab. This review was limited by different patient populations, small numbers, possible inter-pathological discordance, and study heterogeneity. Evidence for nivolumab, pembrolizumab, or durvalumab remains inconclusive.

This review integrates findings from key clinical trials evaluating ICIs, such as pembrolizumab and atezolizumab, used alone or alongside BCG, emphasizing their capacity to elicit sustained therapeutic benefits. ICIs represent a promising therapeutic avenue for patients with BCG-unresponsive NMIBC, supporting a shift toward bladder-preserving management strategies. Future research should focus on biomarker-guided patient selection and explore combination regimens to optimize clinical outcomes, thereby informing both clinical practice and investigational priorities.

Five ICIs may induce skin toxicity events, which exhibit specific population characteristics, temporal patterns, and toxicity profiles. When using the PD-1 inhibitors nivolumab or pembrolizumab, particular vigilance is required for severe cutaneous toxicity to avoid unfavorable outcomes. Expanding the sample size and incorporating machine learning in the future may improve the precision and clinical translatability of signal detection, providing important evidence for optimizing clinical monitoring strategies for ICIs and establishing toxicity early-warning models.

P2, N=81, Active, not recruiting, Institut Curie | Recruiting --> Active, not recruiting | N=130 --> 81

Secondary endpoints include feasibility, safety, post-operative complications, and metabolic response by positron emission tomography. Exploratory studies characterize immune cell infiltration, tumor mutational burden, and circulating tumor DNA dynamics.

Patients with non-small-cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) mutations who experience disease progression after treatment with an EGFR-tyrosine kinase inhibitor (EGFR-TKI) often receive subsequent treatment with either platinum-based chemotherapy (Chemo) or a combination regimen of atezolizumab, bevacizumab, carboplatin, and paclitaxel (ABCP). After propensity score matching, among patients who responded to prior EGFR-TKIs for ≥10 months, the ABCP group had a significantly longer PFS than the Chemo group (8.6 versus 5.3 months; log-rank test, P = 0.008). The efficacy of prior EGFR-TKI treatment in patients with EGFR-mutant NSCLC who experience disease progression could be a predictive marker for ABCP rather than Chemo efficacy.

P3, N=1280, Active, not recruiting, Hoffmann-La Roche | Trial completion date: Dec 2027 --> Aug 2027

P=N/A, N=350, Recruiting, Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | Not yet recruiting --> Recruiting

P1/2, N=2, Terminated, Ariceum Therapeutics GmbH | N=50 --> 2 | Trial completion date: Dec 2026 --> Dec 2025 | Recruiting --> Terminated | Trial primary completion date: Aug 2026 --> Dec 2025; Study terminated due to strategic business decisions.